Syntaxin Ltd. Our lead programme is progressing through a collaboration with Allergan, Inc. to treat pain. This programme entered Phase II in July 2010, for the treatment of post-herpetic neuralgia. Please refer to the following link for further information - Clinical Trials. We also have our own preclinical programme to treat Acromegaly, an orphan indication caused by excess growth hormone secretion. Clinical results are expected in 2012 for our study in Acromegaly. We have a balanced portfolio with regard to achievability and risk. Products are chosen to ensure this balance, as well as strategic partnerships pursued to ensure future success, provide ongoing income and access to therapeutic expertise. We are a private company with a strong investor base including three corporate investors. Abingworth, SR One, J&J Development Corporation, LSP, Quest Management, Ipsen, Lundbeckfond Ventures and Seventure are current investors. The technology was spun out of the Health Protection Agency, who still own a small share of the company.